CA3063535A1 - Fused heteroaromatic-aniline compounds for treatment of dermal disorders - Google Patents

Fused heteroaromatic-aniline compounds for treatment of dermal disorders Download PDF

Info

Publication number
CA3063535A1
CA3063535A1 CA3063535A CA3063535A CA3063535A1 CA 3063535 A1 CA3063535 A1 CA 3063535A1 CA 3063535 A CA3063535 A CA 3063535A CA 3063535 A CA3063535 A CA 3063535A CA 3063535 A1 CA3063535 A1 CA 3063535A1
Authority
CA
Canada
Prior art keywords
compound
formula
alkyl
mek
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3063535A
Other languages
English (en)
French (fr)
Inventor
John Kincaid
Matthew Duncton
Original Assignee
Nflection Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nflection Therapeutics Inc filed Critical Nflection Therapeutics Inc
Publication of CA3063535A1 publication Critical patent/CA3063535A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
CA3063535A 2017-05-19 2018-05-18 Fused heteroaromatic-aniline compounds for treatment of dermal disorders Pending CA3063535A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508997P 2017-05-19 2017-05-19
US62/508,997 2017-05-19
PCT/US2018/033544 WO2018213807A1 (en) 2017-05-19 2018-05-18 Fused heteroaromatic-aniline compounds for treatment of dermal disorders

Publications (1)

Publication Number Publication Date
CA3063535A1 true CA3063535A1 (en) 2018-11-22

Family

ID=62620965

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3063535A Pending CA3063535A1 (en) 2017-05-19 2018-05-18 Fused heteroaromatic-aniline compounds for treatment of dermal disorders

Country Status (13)

Country Link
US (2) US10988483B2 (cg-RX-API-DMAC7.html)
EP (1) EP3624795B1 (cg-RX-API-DMAC7.html)
JP (1) JP7237941B2 (cg-RX-API-DMAC7.html)
KR (1) KR102659322B1 (cg-RX-API-DMAC7.html)
CN (1) CN111093658B (cg-RX-API-DMAC7.html)
AU (1) AU2018270292B2 (cg-RX-API-DMAC7.html)
CA (1) CA3063535A1 (cg-RX-API-DMAC7.html)
DK (1) DK3624795T3 (cg-RX-API-DMAC7.html)
ES (1) ES2913213T3 (cg-RX-API-DMAC7.html)
IL (1) IL270576B (cg-RX-API-DMAC7.html)
MA (1) MA49140A (cg-RX-API-DMAC7.html)
MX (1) MX2019013562A (cg-RX-API-DMAC7.html)
WO (1) WO2018213807A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2913213T3 (es) * 2017-05-19 2022-06-01 Nflection Therapeutics Inc Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos
WO2020106305A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
EP3883552B1 (en) 2018-11-20 2025-04-09 NFlection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
CN113660931B (zh) * 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物
CN113473986B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤疾病萘啶酮苯胺化合物
CN113645964B (zh) * 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于胎记治疗的芳基苯胺和杂芳基苯胺化合物
CN117157065A (zh) 2021-01-21 2023-12-01 恩福莱克逊治疗有限公司 吡咯并吡啶-苯胺化合物的晶型
MX2024011403A (es) * 2022-03-17 2024-09-23 Springworks Therapeutics Inc Tratamiento con mirdametinib.

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7674907B2 (en) * 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
WO2006083979A2 (en) 2005-02-02 2006-08-10 Nexgenix Pharmaceuticals, L.L.C. Local treatment of neurofibromas
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
GB0601962D0 (en) * 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
GB0616214D0 (en) 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
CA2660546A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
WO2008024724A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
EP2113500A1 (en) 2006-10-31 2009-11-04 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
CA2672327A1 (en) 2006-11-30 2008-06-05 Genentech, Inc. Aza-indolyl compounds and methods of use
US20080312307A1 (en) 2007-05-25 2008-12-18 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
GB0714384D0 (en) * 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
CA2708176A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
GB0801081D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
WO2009093008A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
GB0801080D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
JP2010043019A (ja) * 2008-08-12 2010-02-25 Taisho Pharmaceutical Co Ltd ピペリジニルピペラジン化合物
AR082453A1 (es) * 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
US9422262B2 (en) 2010-09-24 2016-08-23 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
US9357781B2 (en) 2013-05-03 2016-06-07 Inscent, Inc. Honeybee repellents and uses thereof
CN105384754B (zh) 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
JP7212956B2 (ja) 2017-05-19 2023-01-26 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用のピロロピリジン-アニリン化合物
ES2913213T3 (es) 2017-05-19 2022-06-01 Nflection Therapeutics Inc Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos

Also Published As

Publication number Publication date
JP7237941B2 (ja) 2023-03-13
JP2020520994A (ja) 2020-07-16
ES2913213T3 (es) 2022-06-01
MX2019013562A (es) 2020-08-03
CN111093658A (zh) 2020-05-01
KR102659322B1 (ko) 2024-04-22
CN111093658B (zh) 2022-10-14
DK3624795T3 (da) 2022-05-23
US11542271B2 (en) 2023-01-03
WO2018213807A1 (en) 2018-11-22
US20200172550A1 (en) 2020-06-04
KR20200026812A (ko) 2020-03-11
MA49140A (fr) 2020-03-25
US20210380601A1 (en) 2021-12-09
IL270576B (en) 2022-01-01
EP3624795B1 (en) 2022-04-20
EP3624795A1 (en) 2020-03-25
US10988483B2 (en) 2021-04-27
AU2018270292B2 (en) 2022-02-10
AU2018270292A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
US12428418B2 (en) Pyrrolopyridine-aniline compounds for treatment of dermal disorders
AU2018270292B2 (en) Fused heteroaromatic-aniline compounds for treatment of dermal disorders
EP3883552B1 (en) Cyanoaryl-aniline compounds for treatment of dermal disorders
EP3883567B1 (en) Naphthyridinone-aniline compounds for treatment of dermal disorders
HK40026703B (en) Fused heteroaromatic-aniline compounds for treatment of dermal disorders
HK40026703A (en) Fused heteroaromatic-aniline compounds for treatment of dermal disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220907

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250425

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250425

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250430

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250819

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250829

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251028

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251028

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260601

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260601